Active ingredient containing miRNA and application thereof
By using miR-302/miR367 family miRNA to inhibit the mTORC2 signaling pathway, the non-alcoholic fatty liver problem caused by over-synthesis of fatty acids under high sugar and high fat pressure was solved, and effective inhibition of NAFLD and improvement of liver in mouse models was achieved. Function.
Patent Information
- Application Number
- CN202411018609.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-12-03
AI Technical Summary
There is a lack of effective treatment for non-alcoholic fatty liver (NAFLD), especially fatty liver problems caused by excessive synthesis of fatty acids under high sugar and high fat pressure.
MiRNA or its derivatives of the miR-302/miR367 family are used to inhibit the mTORC2 signaling pathway and inhibit the de novo synthesis of fatty acids, thereby blocking the excessive synthesis of fatty acids under high sugar and high fat pressure, and are used to treat non-alcoholic fatty liver.
In the mouse model of lipohepatic liver, liver-specific overexpression of miR-302 can effectively inhibit the occurrence of NAFLD, reduce liver fat content and inflammation, improve liver function indicators, and block the de novo synthesis of fatty acids, providing a potential treatment Drugs for alcoholic fatty liver.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
[0001] This application is a divisional application with application number 202310592232.X, application date May 23, 2023, and invention name “Active ingredients containing miRNA and their applications”. Technical Field
[0002] The present application belongs to the field of biomedicine, and specifically relates to active ingredients containing miRNA and their applications. Background Art
[0003] The liver is an important site of sugar and lipid metabolism in the body, and is crucial for maintaining the homeostasis of sugar and lipid synthesis and catabolism. When this dynamic balance is broken, such as excessive intake or increased synthesis of saturated fatty acids, excessive lipid synthesis, reduced apolipoprotein synthesis, and very low-density lipoprotein (VLDL) synthesis disorders, it will cause increased liver fat accumulation and lead to fatty liver. Fatty liver includes NAFLD and alcoholic fatty liver (ALD), which have a wide incidence worldwide. Among them, NAFLD is a clinical pathological syndrome characterized by ectopic precipitation and fatty degeneration of liver triglycerides caused by multiple factors (excluding alcohol). The diagnosis of NAFLD requires the help of imaging and tissue biopsy. When pathological examination of the liver shows more than 5% infiltrative fatty degeneration or the proton density fat fraction (MRI-PDFF) of magnetic resonance imaging exceeds 5%, it can be determined as NAFLD. The occurrence of this disease is significantly associated with multiple risk factors, including dyslipidemia, hypertension, hyperglycemia, insulin resistance, aging, etc. Because the etiology of NAFLD is complex and occurs in tandem with multiple diseases, such as type 2 diabetes mellitus (T2DM), obesity, and intestinal flora disorders, its exact pathogenesis has not been clearly elucidated.
[0004] MicroRNA (miRNA) is a non-coding single-stranded RNA molecule with a length of 18-25 nucleotides encoded by endogenous genes. MiRNA is involved in a variety of biological processes. One way is that miRNA binds to the target gene complementary to the target gene and finally cuts the target mRNA. The second way is that it binds to the target gene in an incompletely complementary way and inhibits the translation of the target gene.
[0005] The seed sequence of miRNA is the most evolutionarily conserved sequence, generally the 2nd to 8th nucleotides at the 5' end. The conservation of the seed sequence and the target sequence constitutes the model basis for target sequence prediction, but the predicted target sequences still need to be experimentally verified.
[0006] Currently, there is a lack of effective therapeutic miRNA drugs related to fatty liver. Summary of the invention
[0007] Based on this, one embodiment of the present application necessarily provides an application of an active ingredient in the preparation of a product for treating non-alcoholic fatty liver disease, wherein the active ingredient can inhibit excessive synthesis of fatty acids under high sugar and high fat pressure, thereby inhibiting the occurrence of fatty liver.
[0008] The specific technical solutions are as follows:
[0009] The present application provides an active ingredient, which includes at least one of the following:
[0010] (1) miRNA of the miR-302 / miR367 family, or a modified miRNA derivative of the miR-302 / miR367 family, or a miRNA mimic of the miR-302 / miR367 family; (2) a precursor miRNA, which can be processed into the miRNA described in (1) in the host; (3) a polynucleotide, which can be transcribed by the host to form the precursor miRNA described in (2), and processed to form the miRNA described in (1); (4) an expression vector, which contains the miRNA described in (1), or the precursor miRNA described in (2), or the polynucleotide described in (3); (5). An agonist of the miRNA described in (1).
[0011] In one embodiment, the miRNA is derived from humans or other animals. Optionally, the other animals include one or more of primates and other mammals, amphibians and birds. Optionally, the other animals include one or more of monkeys, cats, dogs, mice and rats.
[0012] In one embodiment, the miRNA of the miR-302 / 367 family includes one or more of miR-302a, miR-302b, miR-302c, miR-302d, miR-302e, miR-302f and miR-367. Optionally, the miR-302a includes miR-302a-3p and / or miR-302a-5p; the miR-302b includes miR-302b-3p and / or miR-302b-5p; the miR-302c includes miR-302c-3p and / or miR-302c-5p; the miR-302d includes miR-302d-3p and / or miR-302d-5p; the miR-367 includes miR-367-3p and / or miR-367-5p.
[0013] In one embodiment, the miRNA of the miR-302 / 367 family is selected from one or more of the following: hsa-miR-302a-3p, hsa-miR-302b-3p, hsa-miR-302c-3p.1, hsa-miR-302d-3p, hsa-miR-302e, bta-miR-302b, bta-miR-302c, bta-miR-302d, gga-miR-302b-3p, gga-miR-302c-3p, gga-miR-302d, mdo- miR-302a, mdo-miR-302b, mdo-miR-302c, mdo-miR-302d, mml-miR-302a-3p, mml-miR-302b, mml-miR-302c, mml-miR-302d, mm u-miR-302a-3p, mmu-miR-302b-3p, mmu-miR-302d-3p, ptr-miR-302a, ptr-miR-302b, ptr-miR-302c, ptr-miR-302d, ptr-miR- 302e, hsa-miR-302a-5p, cfa-miR-302a, mmu-miR-302a-5p, hsa-miR-302b-5p, hsa-miR-302d-5p, cfa-miR-302b, cfa-miR-30 2d, gga-miR-302b-5p, mmu-miR-302b-5p, mmu-miR-302c-5p, mmu-miR-302d-5p, bta-miR-302a, gga-miR-302a, mmu-miR-302c -3p, hsa-miR-302c-5p, cfa-miR-302c, gga-miR-302c-5p, hsa-miR-302f, ptr-miR-302f, hsa-miR-367-5p, cfa-miR-367, mmu -miR-367-5p, hsa-miR-367-3p, mml-miR-367, mmu-miR-367-3p, ptr-miR-367, gga-miR-367, mml-miR-302a-5p and xtr-miR-367.
[0014] In one embodiment, the nucleotide sequence of the miRNA of the miR-302 / 367 family comprises a nucleotide sequence as shown in at least one of SEQ ID No: 1-2.
[0015] The present application also provides the use of the above-mentioned active ingredients in the preparation of products for treating non-alcoholic fatty liver disease.
[0016] The present application also provides the use of the above-mentioned active ingredients in the preparation of products for treating non-alcoholic fatty liver disease.
[0017] The present application also provides the use of the above-mentioned active ingredients in the preparation of products for treating non-alcoholic fatty hepatitis.
[0018] In one embodiment, the non-alcoholic steatohepatitis or the non-alcoholic fatty liver disease has one or more of the following characteristics:
[0019] (1) Fatty degeneration and fat accumulation;
[0020] (2) lobular inflammation, ballooning, and fibrosis; and
[0021] (3) Increased liver index, increased liver TG content, abnormal liver function indicators ALT and AST, and abnormal serum TCHO and TG.
[0022] In one embodiment, the treatment comprises inhibiting excessive fatty acid synthesis under high-glucose and high-fat stress; optionally, the inhibition is inhibiting de novo fatty acid synthesis in stem cells by inhibiting the mTOCR2 signaling pathway.
[0023] In one embodiment, the treatment includes inhibiting steatosis and fat accumulation caused by non-alcoholic steatohepatitis or non-alcoholic fatty liver disease, as well as lobular inflammation, ballooning and fibrosis.
[0024] In one embodiment, the treatment includes inhibiting the increase of liver index in non-alcoholic steatohepatitis or non-alcoholic fatty liver disease, alleviating liver function indicators ALT and AST, and reducing TCHO and TG.
[0025] Compared with the prior art, this application has the following beneficial effects:
[0026] The present application found in a fatty liver mouse model that liver-specific overexpression of miR-302 can inhibit the occurrence of NAFLD. Therefore, miR-302 is used as a drug for the treatment of non-alcoholic fatty liver disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 Figure A in the figure shows the construction process of pAAV-TBG-miR-302b (mut 5bp), and Figure B shows the schematic diagram of packaging of recombinant AAV virus overexpressing miR-302b;
[0028] Figure 2 The preparation process of Minicircle plasmid;
[0029] Figure 3Schematic diagram of the structure designed for the miRNA sequence;
[0030] Figure 4 The results of Oil Red O staining, where Figures A to D are the control group, FFA-PBS, FFA-miR-302b, and FFA-miR-302b-NC, respectively;
[0031] Figure 5 Figure 1 is the flow cytometry analysis result, where Figure A is the flow cytometry graph and Figure B is the statistical graph of A;
[0032] Figure 6 The results of Western blot detection of mTORC2 signaling-related proteins and downstream fatty acid de novo synthesis-related rate-limiting enzymes, where Figure A is a Western blot image, and Figures B and C are the quantification results of Figure A;
[0033] Figure 7 The following are the construction strategies and mouse administration strategies. Figure A is the construction pattern of the Minicircle plasmid and adeno-associated virus main plasmid for liver-specific expression of miR-302b; Figure B is the procedure for delivering miR-302b to the liver of high-sugar and high-fat mice;
[0034] Figure 8 This is the liver qPCR result;
[0035] Fig. 9 Results of in vivo imaging of small animals;
[0036] Fig.10 Figure A shows liver weight, and Figure B shows liver TG content;
[0037] Fig.11 Results of liver pathology; (A) Results of HE staining and oil red staining of liver pathological sections; (B) Liver fatty degeneration score, N = 6 / group; (C) Lobular inflammation score, N = 6 / group; (D) Ballooning degeneration score, N = 6 / group; (E) Fibrosis score, N = 6 / group; Data statistics are expressed as mean ± s; ** P<0.01, *** P < 0.001;
[0038] Fig.12 Figures A to E in the figure are liver function indexes (ALT, AST), serum TCHO and TG, and NAFLD scores;
[0039] Fig.13 Figure A in the middle is the Western blot detection of the expression of proteins related to mTORC2 signaling and de novo fatty acid synthesis signaling; Figure B is the quantification of Western blot results, N=4 / group. DETAILED DESCRIPTION
[0040] In order to make the above-mentioned purposes, features and advantages of the present application more obvious and easy to understand, the specific implementation methods of the present application are described in detail below in conjunction with the accompanying drawings. In the following description, many specific details are set forth to facilitate a full understanding of the present application. However, the present application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present application, so the present application is not limited by the specific embodiments disclosed below.
[0041] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.
[0042] As used herein, the term "and / or" includes any and all combinations of one or more of the associated listed items.
[0043] Based on this, an embodiment of the present application provides an active ingredient, which includes at least one of the following groups:
[0044] (1) a miRNA or modified miRNA derivative or miRNA mimic comprising at least one of the following core sequences, with a length of 16 nt to 28 nt, and having the same or substantially the same function as miR-302 or miR-367: 5'-AAGUGCU-3', 5'-CUUAAAC-3', 5'-CUUUAAC-3', 5'-AGUGCUU-3', 5'-UUAACAU-3', 5'-AAUUGCU-3', 5'-CUGUUGC-3' and 5'-AUUGCAC-3';
[0045] (2) a precursor miRNA, which can be processed into the miRNA described in (1) in the host;
[0046] (3) a polynucleotide, which can be transcribed by a host to form the precursor miRNA described in (2), and processed to form the miRNA described in (1);
[0047] (4) an expression vector comprising the miRNA described in (1), the precursor miRNA described in (2), or the polynucleotide described in (3);
[0048] (5) An agonist of the miRNA described in (1).
[0049] In a specific example, the miRNA described in (1) can be a mature miRNA.
[0050] The term "miRNA and its precursor" refers to microRNA (miRNA for short), which is an endogenous non-coding single-stranded small RNA of about 22 nucleotides in length that has been found in eukaryotic organisms such as nematodes, fruit flies, plants, and mammals in recent years. It has tissue and time specificity in expression, and negatively regulates gene expression at the post-transcriptional level by complementary base pairing with the target mRNA, resulting in mRNA degradation or translation inhibition, and is an important regulatory molecule for regulating the expression of other functional genes. More and more evidence shows that although miRNA is small, it plays a vital role in various life processes of organisms by forming complete or incomplete mismatches with the target mRNA. As used herein, the "miRNA" refers to a class of RNA molecules that are processed from transcripts that can form miRNA precursors. Mature miRNAs usually have 18-26 nucleotides (nt) (more particularly about 19-22nt), and miRNA molecules with other numbers of nucleotides are not excluded. MiRNAs can usually be detected by Northern blots.
[0051] miRNA can be processed from precursor miRNA (Precursor miRNA, Pre-miRNA), and the precursor miRNA can be folded into a stable stem-loop (hairpin) structure, and the length of the stem-loop structure is generally between 50-100bp or longer. The precursor miRNA can be folded into a stable stem-loop structure, and the stem of the stem-loop structure contains two substantially complementary sequences on both sides. The precursor miRNA can be natural or artificially synthesized. As used herein, "substantially complementary" means that the nucleotide sequences are sufficiently complementary and can interact in a predictable manner, such as forming a secondary structure (such as a stem-loop structure). Usually, at least 70% of the nucleotides of two "substantially complementary" nucleotide sequences are complementary to each other; preferably, at least 80% of the nucleotides are complementary; more preferably, at least 90% of the nucleotides are complementary; further preferably, at least 95% of the nucleotides are complementary; such as 98%, 99% or 100%.
[0052] As used herein, a "stem-loop" structure is also referred to as a "hairpin" structure, and refers to a nucleotide molecule that can form a secondary structure including a double-stranded region (stem), wherein the double-stranded region is formed by two regions of the nucleotide molecule (located on the same molecule), and the two regions are arranged on both sides of the double-stranded portion; it also includes at least one "loop" structure, including a non-complementary nucleotide molecule, i.e., a single-stranded region. Even if the two regions of the nucleotide molecule are not completely complementary, the double-stranded portion of the nucleotide can remain in a double-stranded state. For example, insertion, deletion, substitution, etc. may result in a small region being non-complementary or the small region itself forming a stem-loop structure or other forms of secondary structure, however, the two regions may still be substantially complementary and interact in a predictable manner to form a double-stranded region of the stem-loop structure. The stem-loop structure is well known to those skilled in the art, and generally after obtaining a nucleic acid having a nucleotide sequence with a primary structure, those skilled in the art can determine whether the nucleic acid can form a stem-loop structure.
[0053] As used herein, "the function is the same or substantially the same as miR-302" means retaining ≥50%, ≥60%, ≥70%, ≥80%, ≥90% of the function of miR-302b in reversing the aging process (for example, restoring the cell cycle or cell proliferation of senescent cells).
[0054] The present application also includes miRNA variants and derivatives. A person skilled in the art can modify miR-302 using a common method, including (but not limited to): methylation modification, locked nucleotide modification, nucleic acid modification, hydrocarbon modification, glycosylation modification, peptide modification, lipid modification, halogen modification, etc.
[0055] In one specific example, an agonist of a miRNA includes a substance that promotes miRNA expression or promotes the functional activity of a miRNA, for example, a miRNA mimic comprising a polynucleotide of the initial miRNA (pri-miRNA), precursor miRNA (pre-miRNA) or mature sequence of miR-302a, miR-302b, miR-302c, miR-302d, miR-302e, miR-302f and / or miR-367.
[0056] In a specific example, the miRNA is derived from humans or other animals; preferably, the other animals are one or more of monkeys, cats, dogs, rats and mice.
[0057] In a specific example, the miR-302 / miR367 family comprising the 5'-AAGUGCU-3' core sequence is selected from one or more of the following groups: hsa-miR-302a-3p, hsa-miR-302b-3p, hsa-miR-302c-3p.1, hsa-miR-302d-3p, hsa-miR-302e, bta-miR-302b, bta-miR-302c, bta-miR-302d, gga-miR-302b-3p, gga-miR-302c-3p, gga-miR-302d, mdo-miR-302a-3p, mdo-miR-302e-3p.2, b, mdo-miR-302c, mdo-miR-302d, mml-miR-302a-3p, mml-miR-302b, mml-miR-302c, mml-miR-302d, mmu-miR-302a-3p, mmu-miR-302b-3p, mmu-miR-302d-3p, ptr-miR-302a, ptr-miR-302b, ptr-miR-302c, ptr-miR-302d, ptr-miR-302e; and / or, the miR-302 / miR367 family comprising the 5'-CUUAAAC-3' core sequence is selected from one of the following groups or more: hsa-miR-302a-5p, cfa-miR-302a and mmu-miR-302a-5p; and / or, the miR-302 / miR367 family comprising the 5'-CUUUAAC-3' core sequence is selected from one or more of the following groups: hsa-miR-302b-5p, hsa-miR-302d-5p, cfa-miR-302b, cfa-miR-302d, gga-miR-302b-5p, mmu-miR-302b-5p, mmu-miR-302c-5p and mmu-miR-302d-5p; and / or, the miR-302 / miR367 family comprising the 5'-CUUUAAC-3' core sequence is selected from one or more of the following groups: hsa-miR-302b-5p, hsa-miR-302d-5p, cfa-miR-302b, cfa-miR-302d, gga-miR-302b-5p, mmu-miR-302b-5p, mmu-miR-302c-5p and mmu-miR-302d-5p; and / or, the miR-302 / miR367 family comprising the 5'-AGUGCUU-3' core sequence The miR-302 / miR367 family of the core sequence is selected from one or more of the following groups: bta-miR-302a, gga-miR-302a, mmu-miR-302c-3p; and / or, the miR-302 / miR367 family comprising the 5'-UUAACAU-3' core sequence is selected from one or more of the following groups: hsa-miR-302c-5p, cfa-miR-302c and gga-miR-302c-5p; and / or, the miR-302 / miR367 family comprising the 5'-AAUUGCU-3' core sequence is selected from hsa-miR-302f and / or ptr-miR-302f;And / or, the miR-302 / miR367 family comprising the 5'-CUGUUGC-3' core sequence is selected from hsa-miR-367-5p, cfa-miR-367, mmu-miR-367-5p; and / or, the miR-302 / miR367 family comprising the 5'-AUUGCAC-3' core sequence is selected from hsa-miR-367-3p, mml-miR-367, mmu-miR-367-3p, ptr-miR-367, xtr-miR-367. ;
[0058] In a specific example, the miRNA is a miRNA in the miR-302 / 367 family, and the miR-302 / 367 family includes: miR-302 and / or miR-367, or a modified derivative of miR-302 or miR-367, whose function is the same or substantially the same as that of miR-302b or miR-367. Among them, the miRNA can be a mature miRNA, and the above mature miRNA sequence and its gene coding sequence may have base differences between different species, but it does not affect the performance of its function.
[0059] In a specific example, miR-302 includes one or more of miR-302a, miR-302b, miR-302c, miR-302d, miR-302e and miR-302f; optionally, miR-302a includes miR-302a-3p and / or miR-302a-5p; miR-302b includes miR-302b-3p and / or miR-302b-5p; miR-302c includes miR-302c-3p and / or miR-302c-5p; miR-302d includes miR-302d-3p and / or miR-302d-5p; miR-367 includes miR-367-3p and / or miR-367-5p;
[0060] In a specific example, the miRNA is selected from the following miRNAs in the miR-302 / 367 family:
[0061] hsa-miR-302a-3p(MIMAT0000684)、hsa-miR-302b-3p(MIMAT0000715)、hsa-miR-302c-3p.1(MIMAT0000717)、hsa-miR-302d-3p(MIMAT0000718)、hs a-miR-302e(MIMAT0005931)、bta-miR-302b(MIMAT0009280)、bta-miR-302c(MIMAT0009281)、bta-miR-302d(MIMAT0009279)、gga-miR-302b-3p(MI MAT0003357), gga-miR-302c-3p (MIMAT0003359), gga-miR-302d (MIMAT0003360), mdo-miR-302a (MIMAT0004182), mdo-miR-302b (MIMAT0004180), mdo-miR-302c (MIMAT0004181), mdo-miR-302d (MIMAT0004183), mml-miR-302a-3p (MIMAT0006259), mml-miR-302b (MIMAT0006260), mml-miR-302c (M (MIMAT0006261), mml-miR-302d(MIMAT0006262), mmu-miR-302a-3p(MIMAT0000380), mmu-miR-302b-3p(MIMAT0003374), mmu-miR-302d-3p(MIMAT0003377), ptr-miR-302a(MIMAT0008086), ptr-miR-302b(MIMAT0008087), ptr-miR-302c(MIMAT0008088), ptr-miR-302d(MIMAT0008089), ptr-miR-30 2e(MIMAT0008090)、hsa-miR-302a-5p(MIMAT0000683)、cfa-miR-302a(MIMAT0009855)、mmu-miR-302a-5p(MIMAT0004579)、hsa-miR-302b-5p(MIMA T0000714)、hsa-miR-302d-5p(MIMAT0004685)、cfa-miR-302b(MIMAT0009856)、cfa-miR-302d(MIMAT0009858)、gga-miR-302b-5p(MIMAT0003356)、mmu-miR-302b-5p(MIMAT0003373), mmu-miR-302c-5p(MIMAT0003375), mmu-miR-302d- 5p(MIMAT0017225), bta-miR-302a(MIMAT0009278), gga-miR-302a(MIMAT0001143), mmu -miR-302c-3p(MIMAT0003376), hsa-miR-302c-5p(MIMAT0000716), cfa-miR-302c(MIMA T0009857), gga-miR-302c-5p (MIMAT0003358), hsa-miR-302f (MIMAT0005932), ptr-miR -302f(MIMAT0008091), hsa-miR-367-5p(MIMAT0004686), cfa-miR-367(MIMAT0009859) , mmu-miR-367-5p(MIMAT0017214), hsa-miR-367-3p(MIMAT0000719), mml-miR-367(MIM AT0006292), mmu-miR-367-3p (MIMAT0003181), ptr-miR-367 (MIMAT0008118), gga-miR- 367 (MIMAT0003369), mml-miR-302a-5p (MIMAT0026851) and xtr-miR-367 (MIMAT0003638). ,
[0062] The number in brackets is the accession number, which can be queried in the mirbase database.
[0063] In a preferred example, the miRNA is selected from the following miRNAs in the miR-302 / 367 family: one or more of hsa-miR-302a-3p, hsa-miR-302a-5p, hsa-miR-302b-3p, hsa-miR-302b-5p, hsa-miR-302c-3p, hsa-miR-302c-5p, hsa-miR-302d-3p, hsa-miR-302d-5p, hsa-miR-302e, hsa-miR-302f, hsa-miR-367-5p and hsa-miR-367-3p, or selected from nucleotides with a homology of ≥75% with the above miRNA sequences, preferably a homology of ≥85%, more preferably a homology of ≥95%, and optimally a homology of ≥99%. Furthermore, the miRNA includes the nucleotide sequences shown in SEQ ID NOs: 1-2.
[0064] According to the miRNA sequence provided in the present application, a person of ordinary skill in the art can design a polynucleotide (construct) that can be processed into a miRNA that can affect the expression of the corresponding mRNA after being introduced, that is, the polynucleotide (construct) can upregulate the function of the corresponding miRNA in vivo. Therefore, one embodiment of the present application also provides a separated polynucleotide (construct), the polynucleotide (construct) can be transcribed into a precursor miRNA by a human cell, and the precursor miRNA can be cleaved and expressed into the miRNA by a human cell.
[0065] Usually, the polynucleotide construct is located on an expression vector. Therefore, the present application also includes a vector containing the miRNA, or the polynucleotide (construct). The expression vector usually also contains a promoter, a replication origin and / or a marker gene, etc. Methods well known to those skilled in the art can be used to construct the expression vector required for the present invention. These methods include in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, etc. The expression vector preferably contains one or more selective marker genes to provide phenotypic traits for selecting transformed host cells.
[0066] In a specific example, the derivative or the expression vector described in or described in the polynucleotide comprises the structure shown in Formula I:
[0067] Seq 正向 -X-Seq 反向 Formula I;
[0068] In Formula I, Seq 正向 is a nucleotide sequence that can be processed into any miRNA in the miRNA-302 / miRNA-367 family in the host, Seq 反向For Seq 正向 Substantially complementary nucleotide sequences; or, Seq 反向 is a nucleotide sequence that can be processed into any miRNA in the miRNA-302 / miRNA-367 family in the host, Seq 正向 For Seq 反向 Substantially complementary or completely complementary nucleotide sequences; X is a spacer sequence located between Seq forward and Seq reverse, and the spacer sequence is 正向 and Seq 反向 Not complementary;
[0069] And after the structure shown in Formula I is transferred into the host, a secondary structure shown in Formula II is formed:
[0070]
[0071] In Formula II, Seq 正向 , Seq 反向 and X is defined as above,
[0072] || means in Seq 正向 and Seq 反向 The base pairing relationship formed between them.
[0073] In a preferred example, the precursor miRNA or the polynucleotide or the expression vector comprises a nucleotide sequence as shown in any one of SEQ ID Nos: 1 to 2, for example, the nucleotide sequence of the precursor miR-302b is shown in SEQ ID No: 3.
[0074] In a specific example, the expression vector can be selected from a viral vector or a non-viral vector, wherein the non-viral vector includes one or more of a plasmid, a phage, a lipid nanoparticle (LNP), a transfection reagent and an exosome.
[0075] Optionally, the plasmid includes a combination of one or more of pCMV-myc, pcDNA3.0, pcDNA3.1 and Minicircle.
[0076] Preferably, the plasmid is Minicircle, which can carry the target gene with a minimum number of bp and can be continuously expressed in animals.
[0077] Optionally, the viral vector is selected from one or more of a retroviral vector, a lentivirus, an adenoviral vector, an adeno-associated viral vector, a herpes virus vector, an alphavirus vector, a baculovirus and a vaccinia virus, preferably an adeno-associated viral vector, such as an AAV virus.
[0078] One embodiment of the present application also provides the use of a reagent for detecting the above-mentioned miRNA in the preparation of a product for diagnosing fatty liver.
[0079] In one specific example, the reagents include primers and / or probes.
[0080] One embodiment of the present application also provides the use of the above active ingredients in the preparation of a product for treating non-alcoholic fatty liver disease. Further, the non-alcoholic fatty liver disease is non-alcoholic fatty liver disease caused by high sugar and high fat stress.
[0081] In a specific example, the product has the effect of inhibiting excessive synthesis of fatty acids under high sugar and high fat stress.
[0082] In a specific example, the product can effectively block the increase in liver index, increase in liver TG content, abnormal liver function indicators (ALT, AST), and abnormal serum TCHO and TG caused by high sugar and high fat.
[0083] In a specific example, abnormal lipid metabolism has one or more characteristics of excessive fatty acid synthesis, abnormal signaling pathways for de novo fatty acid synthesis (such as mTORC2 signaling), and abnormal expression of downstream rate-limiting enzymes related to de novo fatty acid synthesis.
[0084] In one specific example, the product includes a formulation and / or a pharmaceutical composition.
[0085] In a specific example, the drug includes any of the active ingredients described above and a pharmaceutically acceptable excipient or carrier.
[0086] In a specific example, the excipients include solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesive agents, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids and release retardants. One or more.
[0087] In a specific example, the pharmaceutically acceptable carrier is selected from the group consisting of water, saline, liposomes, lipids, proteins, protein-antibody conjugates, peptides, cellulose, nanogels, or combinations thereof. The choice of carrier should match the mode of administration, which are well known to those of ordinary skill in the art.
[0088] Generally, the dosage form of the drug should match the mode of administration. In a specific example, the dosage form of the drug of the present application includes one or more of injection, oral liquid, suspension, emulsion, extract, powder, granule, suppository, aerosol, transfection agent, tablet and capsule.
[0089] The drugs described in the present application can be administered alone or in combination with other drugs capable of treating the same disease.
[0090] One embodiment of the present application also provides a pharmaceutical composition, which comprises any of the active ingredients described above.
[0091] In a specific example, the DNA sequence encoding the above-mentioned miRNA is used as the target gene, such as miR-302b (SEQID No: 3), an overexpression vector of the miRNA is constructed, and a drug containing the miRNA overexpression vector is prepared and administered via an ex vivo or in vivo administration route.
[0092] Specifically, a person skilled in the art can administer the drug via an ex vivo administration route: the drug of the miRNA overexpression vector is introduced or transfected into the individual's own or allogeneic cells in vitro, and then the cells are amplified in vitro and then injected back into the individual.
[0093] Specifically, a person skilled in the art may also administer the drug via an in vivo administration route: directly introducing the drug of the miRNA overexpression vector into an individual.
[0094] The effective amount of the active ingredient described in the present application may vary depending on the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). Among them, factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated, the patient's weight, the patient's immune status, the route of administration, etc.
[0095] The embodiments of the present application will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance provided in the present application, and can also be based on the experimental manual or normal conditions in this area, can also be based on the conditions recommended by the manufacturer, or refer to experimental methods known in the art.
[0096] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.
[0097] Example 1 Preparation of liver-specific adeno-associated virus overexpressing mir-302b
[0098] (1) The sequences of miR-302b-3p and miR-302b-5p are:
[0099] 5'-UAAGUGCUUCCAUGUUUUAGUAG-3', SEQ ID No: 1, and
[0100] 5'-ACUUUAACAUGGAAGUGCUUUC-3', SEQ ID No: 2;
[0101] The precursor sequence (WT) was designed as follows:
[0102] 5'-GCTCCCTTCA ACTTTAACATGGAAGTGCTTTC TGTGACTTTAAAAG TAAGTGCT TCCATGTTTTAGTAG GAGT-3', SEQ ID No: 3;
[0103] The precursor sequence was mutated by 3 bases as a control, and the sequence is as follows:
[0104] 5'-GCTCCCTTCA ATCCTAACATGGAAGTGCTTTC TGTGACTTTAAAAG TAAGTGCTT CCATGTTTTAGTAG GAGT, SEQ ID No: 4 (the underlined sequence is miR-302b and the bold sequence is 3 mutant bases). Upstream Flanking sequence (200 bp), downstream Flanking sequence (200 bp) and the final synthetic sequence:
[0105] 5'-aaaggaattcaagagttaagaatagtataaatagaagtggctgaagtccctgccttttacccttctggaggagaacacgaatctttgg gaactagttcaggaaggtaaaaaaatttttttcttctaaagttatgccattttgtttctttctcctcagctctaaatactctgaagtccaaagaagttgtatgttgggtggGCTCCCTTCAACTTTAACATGGAAGTGCTTTCTGTGACTTTAAAAGTAAGTGCTTCCATGTTTTAGTAGGAGTgaatccaattt acttctccaaaatagaacacgctaacctcatttgaagggatcccctttgctttaacatgggggtacctgctgtgtgaaacaaaagtaagtgcttccat gtttcagtggaggtgtctccaagccagcacaccttttgttacaaaatttttttgttattgtgttttaaggttactaagcttgttacaggtt-3', SEQ ID No: 5.
[0106] (2) The AAV vector rAAV-TBG-sfGFP-3×FLAG-WPRE provided by Heyuan Biotechnology Co., Ltd. was used to construct a recombinant vector overexpressing miR-302b. The above-mentioned final synthetic sequence was inserted into the downstream of the liver-specific promoter TBG in the expression vector by homologous recombination to construct a recombinant plasmid. The clones were selected and sent to the company for sequencing. The plasmid with correct sequencing was named AAV-miR-302b. The recombinant plasmid with 5 base mutations in miR-302b was constructed by the same method and named AAV-miR-302b-Mut (construction process see Figure 1 A).
[0107] (3) The recombinant vector constructed in (2) was transfected into HEK293T cells. Cell samples were collected 24 hours later, miRNA was extracted, and the miR-302b content in the cells was determined by real-time quantitative PCR using the tailing method.
[0108] (4)7×10 6HEK293T cells / well were inoculated into 15 cm cell culture dishes. The cell culture medium was DMEM containing 10% FBS. The dishes were placed in a 37°C, 5% CO2 incubator for about 24 hours to allow the cell confluence to reach 70% to 80%. Before cell transfection, the complete culture medium was replaced with Opti-DMEM culture medium. The transfection reagent Tubofect TM Transfection Reagent (Invitrogen, Cat # R0532) was transfected according to the operating instructions, and the specific steps were as follows: take a 5mL DNase / RNase-free centrifuge tube, add 500μL Opti-DMEM medium, add the recombinant expression plasmid rAAV-TBG-miR-302b (20μg), serum type plasmid rAAV2 / 8-Rep / Cap (10μg) and virus packaging auxiliary plasmid rAAV-Helper (30μg) to the above centrifuge tube, and vortex mix; take another 5mL DNase / RNase-free centrifuge tube, add 500μL Opti-DMEM medium, add 120μL Tubofect according to the ratio of plasmid mass: transfection reagent volume = 1:2, and vortex mix; mix the two tubes of solution and let it stand at room temperature for 15min; slowly add the liquid after standing to the HEK293T cells prepared previously, drop it in a concentric circle manner, shake it slightly while adding, and then place it at 37℃, 5% CO2 incubator. After 12 h, Opti-DMEM was replaced with complete medium. The recombinant AAV packaging process is shown in Figure 1 B in.
[0109] (5) Observe the cell status. During this period, an appropriate amount of complete culture medium can be added to the culture dish. The packaged virus was collected 72 hours after transfection. The specific steps are as follows: collect the cell supernatant and the cells into the same centrifuge tube, centrifuge at 2100×g for 10 min at room temperature, then transfer the supernatant to a new centrifuge tube, precipitate with PEG 8000 overnight (add 2.33g NaCl and 8.5g PEG 8000 for every 100mL supernatant), and the next day, centrifuge at 3500×g and 4°C for 30min, immediately discard the supernatant to prevent the virus from re-dissolving, and resuspend in 2mL PBS+0.001% PF68; resuspend the above centrifuged cell pellet with 2mL PBS+0.001% PF68, freeze-thaw repeatedly at -80°C and 37°C for 3 times, and add 2mL 5M NaCl (autoclaved); mix the above PEG-precipitated cell supernatant and the resuspended cell pellet, oscillate and sonicate (sonicate for 30s, stop for 8-10s), and AMPL Ultrasonicate at 30% for 3 to 4 times. If the viscosity of the sample decreases, switch to AMPL 20% for 1 time (the purpose of switching the ultrasound intensity is to prevent excessive ultrasound intensity from affecting the activity of the virus); centrifuge the liquid after ultrasound at 3500×g and 4°C for 30 minutes, and transfer the supernatant to a new centrifuge tube.
[0110] (6) Purify the prepared AAV using iodixanol gradient centrifugation. The specific method is as follows: prepare different concentrations of iodixanol (iodixanol and sterile water are prepared according to the mass / volume ratio (Table 1) and then filtered through a 0.22 μm filter membrane); take a high-pressure sterilized ultracentrifuge tube and add different concentrations of iodixanol layer by layer, from bottom to top, 4.2 mL 60% layer, 5 mL 40% layer, 6 mL 25% layer, 9 mL 15% layer (when adding different concentrations of iodixanol, the centrifuge tube should be tilted to avoid layer confluence. The density difference between the 15% layer and the 25% layer is small, so special attention should be paid). The whole process is carried out in a biological safety cabinet; slowly add the virus prepared in (5) to the upper layer, balance the centrifuge tube (control the error within 0.01 g), prepare a VTi50 rotor, and centrifuge at 48,000 rpm and 4°C for 150 min.
[0111] Table 1 Iodixanol density gradient centrifugation solution preparation
[0112]
[0113]
[0114] (7) After ultracentrifugation, puncture the bottom of the ultracentrifugation tube with a needle, discard the 2 mL of liquid that drips, collect the 3rd to 7th mL of liquid, add double antibody to the collected virus, treat at 37°C for 1 hour, then dilute to an appropriate volume with PBS + 0.001% PF68, and sterilize through a 0.22μm filter membrane; transfer the filtrate to a 100KD ultrafiltration tube, centrifuge at 3500rpm and 4°C for 30min; mix the remaining liquid in the ultrafiltration tube by blowing, aspirate and transfer to a virus collection tube, wash the concentration tube twice with 150μL of PBS + 0.001% PF68, transfer the remaining liquid to a virus collection tube, mark the name and date, and store it at -80°C for a long time.
[0115] (8) Take 10 μL of virus for titer determination. Real-time quantitative PCR is a commonly used method for determining the number of purified virus particles. There is a linear relationship between the Ct value of the template and the logarithm of the initial copy number of the template. A standard curve is drawn using a standard substance with a known copy number, and then the number of virus particles is calculated. The specific operation steps are as follows: dilute the virus sample 10 times, prepare Mixture (DNase / RNase-free ddH2O 4μL, DNAasel 1μL, 10×DNAasel Buffer 1μL, virus diluent 4μL), incubate at 37°C for 30min, and inactivate the DNA enzyme at 95°C for 5min; add 1μL proteinase K (5μg / μL), incubate at 37°C for 30min, then add 30μL ultrapure water, heat at 95°C for 5min to inactivate proteinase K, centrifuge at 12000rpm for 2min, and take the supernatant for qPCR detection; take 5μL of the centrifuged supernatant, dilute 10 times, and take 2μL of the dilution as a template for qPCR; calculation of the number of virus particles: number of virus particles (VP / mL) = relative value to the standard × 1000.
[0116] Example 2 Construction of Minicircle expression plasmid
[0117] Minicircle plasmid lacks antibiotic resistance and replication initiation sites, can achieve transient expression in vivo and in vitro, and will not cause immune responses caused by bacterial backbone proteins. Minicircle DNA can achieve sustained expression in vitro and in vivo, and has achieved a 10- to 1000-fold enhancement compared to conventional plasmids, which may be related to the presence of methylation in the backbone plasmid and transgene silencing-induced heterochromatin. SBI's MC-Easy system can produce high-quality Minicircle plasmid in a simple, reproducible and efficient manner, and degrade contaminated genomic DNA with ATP-dependent DNAse reagents, effectively removing genomic DNA without affecting the production of circular DNA plasmids (see the preparation process). Figure 2 ).
[0118] The steps for preparing the Minicircle plasmid overexpressing miR-302b-3p in this example are as follows:
[0119] (1) Design of double-stranded miR-302b-3p sequence: Minicircle parent plasmid pMC.CMV-MCS-EF1α-GFP-SV40-polyAParental Minicircle Cloning Vector (SBI, Cat. # MN511A-1) contains CMV-driven expression of exogenous genes in the MCS region, EF1α promoter-driven expression of GFP, and is resistant to puromycin. The miR-302b-3p sequence inserted in the MSC region must be a sense strand and an antisense strand, and form a stem-loop structure after transcription. There is a hairpin structure between the sense strand and the antisense strand, and the commonly used 12-nt loop sequence is 5'-CTTCCTGTCAGA-3'. Add the TTTTT terminator sequence (RNA polymerase III recognition sequence), and add BamH I and EcoR I restriction endonuclease sites. Note: If it is an H1 promoter, there is no need to add G at the first position of the sense strand, and RNA polymerase III can start transcription from any +1 (second) nucleotide of the H1 promoter; if it is a U6 promoter, G needs to be added before the first position of the sense strand so that RNA polymerase III can preferentially recognize ( Figure 3 The designed sequence was sent to Shanghai Bioengineering Co., Ltd. for synthesis.
[0120] (2) Preparation of double-stranded miR-302b-3p: The DNA oligo to be annealed was prepared into 50 μM with sterile water, and the mixed solution was prepared according to the following system: Nuclease-Free water 40 μL, Annealing Buffer for DNA Oligos (5×) (Biyuntian, Cat. # D0251) 20 μL, DNA oligo A (50 μM) 20 μL, DNA oligo B (50 μM) 20 μL; annealing reaction was performed according to the following PCR reaction program: 95°C for 2 min, decreasing by 0.1°C every 8 s until it dropped to 25°C (about 90 min), 4°C forever.
[0121] (3) Double-stranded miR-302b-3p was connected to the linearized parent plasmid using BamH I (NEB, Cat. # R0136) and EcoRI (NEB, Cat # R0101) was linearized according to the instructions, digested at 37°C overnight, and the gel recovery kit (Vazyme, Cat #DC301-01) to recover DNA fragments; the annealed double-stranded miR-302b-3p sequence was connected to the linearized parent plasmid, and the insert fragment: vector was carried out at a ratio of 3:1. TM T4 DNA Ligase Master Mix (Thermo, Cat # The ligation was carried out according to the instructions of IVGN2104 and the ligation was carried out at 16°C overnight.
[0122] (4) Transformation of ZYCY10P3S2T E.coil with ligation product: This competent state was prepared by transforming strain BW27783 by Kay et al., which can stably express the inducible assembly enzyme ФC31 and I-SceI homing nuclease. The steps for transforming the competent state with ligation product are as follows: take out the competent state and freeze-thaw on ice; add 5μL ligation product to 100μL competent state and vortex to mix; incubate on ice for 30min, heat shock at 42℃ for 30s without shaking, and keep on ice for 2min. Add 200μL S.OC medium to the above reaction product and shake at 250rpm and 37℃ for 90min. At the same time, set up the parent plasmid empty load control and shake at 250rpm and 37℃ for 60min. Apply 200μL bacterial solution on Kan. + On the resistant LB solid medium (containing kanamycin 50μg / mL), the culture plate is preheated to 37℃ (overcooling will reduce the transformation efficiency of the competent state), and the culture plate is cultured at 37℃ overnight. Note: Keep the remaining bacterial solution at room temperature and avoid contamination. If no colonies are seen the next day, the remaining bacterial solution can be smeared on a new culture plate. Pick 3 to 5 clones to 2mL Kan + LB medium, shake the bacteria at 37℃ overnight, extract the plasmid, send it to the company for sequencing, and transfer part of the identified bacterial solution to Kan + The plasmid was amplified in LB medium, and its concentration was determined. Glycerol was added to a portion of the plasmid and the plasmid was frozen at -80°C for later use.
[0123] (5) Induction of Minicircle plasmid: Follow the Minicircle plasmid induction kit MC-EasyMinicircle DNA Production Kit (SBI, Cat. # MN925A-1) was induced. 100 μL of positive bacterial solution was added with 2 mL of Kan + LB medium, shake at 30°C, 250 rpm for 4-6 hours, then take 500 μL and transfer to 200 mL 1× Growth medium (SBI, Cat # MN910A-1-SBI), shake overnight at 30℃ and 250rpm. Note: The bacterial solution must be fresh.+ LB culture plates should not be stored at 4°C for more than 5 days, and the overnight shaking of bacterial solution should not exceed 16 hours. Excessively old bacteria will cause contamination of the parent plasmid and genomic DNA. After shaking overnight, measure pH and OD600. If OD600>8 and pH<6.5, it is recommended to restart the protocol and check whether the temperature and ventilation of the incubator are normal; if OD600 is between 4 and 6, mix 200mL of overnight cultured bacterial solution with 200mL of fresh 1×Induction medium (SBI, Cat. # MN910A-1-SBI); if OD600 is between 6 and 8, mix 200mL of overnight culture with 400mL of fresh 1×Induction medium; continue to shake the mixture at 30℃ and 250rpm for 3h, then increase the temperature to 37℃ and shake at 250rpm for 1h. The total shaking time is 4h. Do not shake for too long, otherwise it will cause bacterial death and genomic DNA contamination. Take 1mL of bacterial culture, extract plasmids, and perform restriction enzyme digestion identification. Strains that have been identified correctly can be used for large-scale plasmid extraction.
[0124] The above-mentioned method for inducing Minicircle plasmid is operated according to the MC-Easy Minicircle DNA Production Kit of SBI. Here is another induction method, which is as follows: positive bacterial solution is cultured overnight to make the bacterial solution OD600 between 3.5 and 4.2, and the pH is about 6.5. 400mL of bacterial solution and 400mL of fresh LB medium, 16mL of NaOH (40g / L), 0.4mL of 20% L-arabinose (SBI, Cat#MN850A-1) are mixed, and the mixture is shaken at 32°C and 250rpm for 5h. 1mL of bacterial culture is taken, and plasmid is extracted and identified by restriction endonuclease digestion. The strains that are correctly identified can be used for large-scale plasmid extraction.
[0125] (6) Removal of genomic and parent plasmid DNA contamination: Use Snapegene software to screen suitable endonucleases for digestion of parent backbone plasmids without affecting the stability of Minicircle plasmids. Use Minicircle-safeDNase (SBI, Cat #MN925A-1) digested the linearized parental plasmid DNA and genomic DNA, the reaction system is as follows: 25mMATP, 20μL; 10×Reaction Buffer, 50μL; DNase, 20μL; extracted plasmid, 410μL; incubated at 37℃ overnight; incubated at 70℃ for 30min to inactivate DNase. Take 2μL of the above DNase-treated plasmid and untreated plasmid and digest and identify them with the selected restriction endonuclease, and detect by agarose gel electrophoresis. If only Minicircle DNA appears, it means that the genomic and parental plasmid DNA has been successfully removed.
[0126] (7) Reprecipitation of Minicircle plasmid: The purpose of this step is to remove DNase and restriction endonuclease contamination. The specific steps are as follows: add 1 / 10 volume of Precipitation Buffer to the DNase-treated Minicircle plasmid solution and mix by pipetting; add 100% ethanol (2 times the volume of Minicircle plasmid solution) or 10.7 times the volume of 100% isopropanol and mix by pipetting; let stand on ice for 30 min, centrifuge at 4°C and 15,000×g for 15 min, and carefully remove the supernatant; add 1 mL of 70% ethanol, centrifuge at 4°C and 15,000×g for 5 min; dry at room temperature for 5 min; add 1 to 2 mL of DNAse-free ddH2O to dissolve, and store at -80°C for later use.
[0127] (8) Removal of ATP and dNTPs (optional): Use a 2 mL DNA centrifuge tube Ultra-2mL CentrifugalFilters (Sigma, Cat # C86533) to remove dNTPs, primers, other macromolecular components, salt ions and buffers. The specific steps are as follows: insert the Centrifugal Filter into the collection tube, add 2 mL of sample, centrifuge at 3000×g, 4℃ for 10 min in an angle rotor; add 2 mL of Wash buffer, centrifuge at 3000×g, 4℃ for 10 min in an angle rotor; separate the Centrifugal Filter and the collection tube, immediately invert the Centrifugal Filter, put it into the collection tube, centrifuge at 300-1 000×g, 4℃ for 2 min, and transfer the concentrated sample to the collection tube; NanoDrop to measure the concentration, A260 and A280 of the collected Minicircle plasmid, the ratio of A260 / A280 should be 1.8-1.9, collect the Minicircle plasmid, and store it at -80℃ for later use.
[0128] (9) In vitro expression verification of Minicircle plasmid: 1.5×10 5 NCTC1469 cells / well were inoculated into 12-well plates; the cells were cultured in a 37°C, 5% CO2 incubator overnight until the confluence of the cells reached about 70%; 1 μg Minicircle plasmid was added to 100 μL DMEM, vortexed to mix, and then 2.5 uL Tubofect transfection reagent was added, and vortexed to mix, and the mixture was allowed to stand at room temperature for 15 min; the mixture was added dropwise in a clockwise concentric circle manner, and shaken crosswise. After 24 hours of transfection, the GFP signal was observed using an FV3000 laser confocal microscope (Olympus) and photos were collected.
[0129] Example 3 Isolation of primary mouse liver cells
[0130] Reagent preparation: D-Hanks solution, Hanks solution, PBS, 1640 complete medium (10% FBS, 1% double antibody), William E medium (10% FBS, 1% double antibody), collagenase II, 5% chloral hydrate, sterile surgical instruments, 100mm culture dish, 15mL / 50mL centrifuge tube, 200 mesh filter, 20mL syringe, scalp needle, pipette, 75% alcohol.
[0131] Operating procedures:
[0132] (1) Preheat perfusion solution I (D-Hanks solution with 0.058 g / L EDTA and 2.383 g / L HEPES) and enzyme solution (solution II with 0.025% collagenase II and 0.5% BSA) at 37°C.
[0133] (2) Treat the culture dish with coating solution for 1 hour, then discard and air dry.
[0134] (3) The mouse was anesthetized and disinfected with 75% alcohol. The limbs were fixed and the abdominal cavity was opened. The superior vena cava in front of the liver was ligated with a hemostatic forceps. The needle was inserted from the inferior vena cava and the perfusion fluid I was slowly pushed in to confirm that the fluid flowed into the blood vessels. After the liver became larger, the portal vein was immediately cut and perfused evenly at a low speed of about 20 mL / 10 min until all the blood was perfused.
[0135] (4) Replace with 20 mL of enzyme solution containing 0.025% collagenase II, 20 mL / 5 min. After completion, digest in situ for 3 min (a well-digested liver will rebound more slowly after being pressed).
[0136] (5) Remove the liver, add 10 mL of pre-cooled 1640 culture medium into a 100 mm dish, and gently crush the liver tissue with forceps.
[0137] (6) Filter through a sieve and use a small amount of culture medium to remove residual tissue pieces and control the total volume to 30 mL.
[0138] (7) Centrifuge at 50 g for 3 min (4°C). The supernatant is non-parenchymal cells and the precipitate is parenchymal cells.
[0139] (8) Discard the supernatant, resuspend the pellet in 10 mL of 1640 medium, centrifuge at 800 rpm for 5 min, and resuspend once.
[0140] (9) Trypan blue staining and counting, the cells were diluted to 2×10 5 / ml, cells with good vitality will adhere to the wall after 3 hours. After the cells adhere, the supernatant is aspirated, the non-adherent cells are removed, and William E medium is used for culture.
[0141] Example 4 Establishment of fatty liver cell model
[0142] (1) Solution preparation: Weigh 7.21 g of fructose into 10 mL of DMEM high-glucose medium to prepare a 4 M stock solution.
[0143] (2) Preparation of high-fat complete medium: F12 and DMEM medium were mixed in a ratio of 2:8, and the prepared fructose solution was added to make the final concentration 4 mM. The oleic acid (OA) storage solution was diluted 50 times, and the palmitic acid (PA) storage solution was diluted 100 times. The high-fat complete medium was prepared by adding the above culture medium and used immediately after preparation.
[0144] (3) The cells isolated in Example 10 were cultured at a rate of 1×10 4 ~1×10 5 The cells were seeded into 6-well plates and cultured in complete medium for 12 h.
[0145] (4) Wash twice with PBS, add 2 mL of high-fat complete medium, and perform Oil Red O staining after 24 hours. The results are shown in the table. Figure 4 In AB, compared with the Contro group, the oil red in the FFA-PBS group model group showed a large number of lipid droplets, indicating successful modeling.
[0146] Example 5: miR-302b inhibits excessive fatty acid synthesis under high-sugar and high-fat stress
[0147] The synthesized miR-302b mimic was transfected into the fatty liver cells prepared in step (4) of Example 11 and simultaneously transfected with miR-302b mimic, and Oil Red O staining was performed 24 hours later.
[0148] Oil red O staining results are shown in Figure 4 As shown, Figure 4 C in the figure is the result of fatty liver model + miR-302b treatment, and the results show that no large amount of lipid droplets were observed. Figure 4D in the figure is the result of fatty liver model + miR-302b-NC, which shows obvious lipid droplet aggregation after mutation of 3 bases.
[0149] The miR-302b-NC control sequence is as follows:
[0150] Forward: UUCUCCGAACGUGUCACGUTT, SEQ ID No: 6,
[0151] Reverse: ACGUGACACGUUCGGAGAATT, SEQ ID No:7.
[0152] These results indicate that miR-302b transfection can effectively block the intracellular fatty acid (FFA) accumulation caused by high-glucose and high-fat stress.
[0153] The results of flow cytometry analysis after BDOIPY staining are shown in Figure 5 , further supporting that miR-302b can inhibit the accumulation of fatty acids in cells.
[0154] Studies have shown that mTORC2 signaling can regulate the de novo synthesis of fatty acids. We used Western blot to detect the expression of mTORC2 signaling-related proteins and downstream rate-limiting enzymes related to de novo synthesis of fatty acids. Figure 6 As shown in the results, it was found that miR-302b transfection can effectively reduce the expression of phosphorylated AKT and phosphorylated GSK3β. In addition, SREBP1c can activate the transcription of genes related to glycolysis and lipogenesis, and plays an important role in the regulation of lipid metabolism and glucose homeostasis. After mTORC2 signal inhibition, the expression of SREBP1c was also significantly reduced, and the expression of the rate-limiting enzymes related to the de novo synthesis of fatty acids (pACLY, ACC, FASN, SCD) in its downstream was significantly decreased. These results indicate that miR-302b can inhibit the mTOCR2 signal and thus inhibit the de novo synthesis of fatty acids in hepatocytes.
[0155] Example 6 Establishment of mouse fatty liver model
[0156] We used a high-fat diet to construct a diabetes-associated fatty liver model (Bi Y, Guo X, Zhang Met al. Bone marrow derived-mesenchymal stem cell improves diabetes-associated fatty liver via mitochondria transformation in mice). Based on the original work and in combination with existing research reports, we optimized the construction method and used a high-fat diet combined with fructose drinking water to construct a disease model. The specific treatment methods are as follows:
[0157] 7-week-old C57BL / 6 male mice were raised under standard SPF conditions, 5 mice / cage, 12h cycle light, 40-60% humidity, constant temperature 22℃, and free access to food and water. After 1 week of adaptive feeding, the animals were randomly divided into 2 groups: the normal group was given a 4% fat maintenance feed and normal drinking water (ND group); the control group was given a high-fat feed with 60% fat content and 5% fructose drinking water (HFD-PBS group). During the experiment, the body weight and blood glucose of the mice were measured once every 2 weeks, and 100μL of orbital venous blood of the mice was collected by capillary tube for biochemical index determination. The results showed that the body weight of mice in the HFD-PBS group was significantly higher than that of the ND group from the 6th week to the end of the experiment. The mice were obese at the end of the experiment, with an average body weight of (46.42±3.51) g. From the 14th week, the lowest body weight of mice in the HFD-PBS group exceeded 40 g. Blood glucose monitoring showed that the blood glucose concentration of mice in the HFD-PBS group began to rise rapidly from the 12th week, and was significantly higher than that of the ND group from the 14th week, with an average blood glucose concentration of (14.36±0.91) mM at the end of the experiment. The GTT test showed that the blood glucose concentration of mice in the HFD-PBS group increased significantly after intraperitoneal injection of glucose, and was still higher than 11.1 mM 2 hours later. The ITT test showed that the blood glucose concentration of mice in the HFD-PBS group was still significantly higher than that of the ND group after intraperitoneal injection of insulin, and it rose rapidly again after 60 minutes. These results showed that the pancreatic islet function of mice in the HFD-PBS group was impaired and insulin resistance occurred. According to the diagnostic criteria, mice with a body weight exceeding 40 g for four consecutive weeks, fasting blood glucose exceeding 6.1 mM, and blood glucose concentration exceeding 11.1 mM 2 hours after intraperitoneal injection of glucose are diagnosed with type 2 diabetes (T2D). Therefore, we successfully established a method to induce a T2D model.
[0158] Example 7 Liver-specific overexpression of miR-302b inhibits the occurrence of NAFLD
[0159] In order to verify the intervention effect of miR-302b on NAFLD, we used AAV and Minicircle plasmid (MC) systems to deliver miR-302b, causing it to be specifically overexpressed in the mouse liver ( Figure 7 A in the figure). The experimental design was divided into 6 groups: ND group, normal diet and water; MC-miR-302b group, high sugar and high fat diet, tail vein injection of 1.5μg / g MC-miR-302b, mixed with an appropriate proportion of Lipo3000 transfection reagent (Thermo), a total volume of 200μL, once a week; AAV-miR-302b group, high sugar and high fat diet, tail vein injection of 1.0E+11 / 200μL AAV-miR-302b, once; Control group, high sugar and high fat diet, tail vein injection of 200μL PBS, once a week; MC-miR-302b-Mut group: high sugar and high fat, tail vein injection of 1.5μg / g MC-miR-302b-Mut (seed sequence mutation of 5 bases), mixed with Lipo3000 transfection reagent in an appropriate proportion, with a total volume of 200 μL, once a week; AAV-miR-302b-Mut group: high sugar and high fat, tail vein injection of 1.0E+11 / 200 μL AAV-miR-302b-Mut, once ( Figure 7 In B), the 9th week was used as the experimental endpoint for detection and analysis.
[0160] qPCR detection found that the livers of mice in the MC-miR-302b group and the AAV-miR-302b group had high abundance of miR-302b ( Figure 8 Small animal in vivo imaging showed that AAV-miR-302b and MC-miR-302b still had fluorescent signals in the liver 9 weeks after tail vein injection ( Fig. 9 ). After 9 weeks, the liver weight of mice was measured ( Fig.10 A) and liver TG content ( Fig.10 B).
[0161] The results of liver pathological analysis were as follows Fig.11 As shown in the results, it was found that the degree of liver steatosis and fat accumulation caused by high sugar and high fat were also blocked by the high expression of miR-302b. The steatosis, lobular inflammation, ballooning and fibrosis in the NAFLD score were also blocked by the high expression of miR-302b.
[0162] Liver delivery of miR-302b can effectively block the increase in liver index, increase in liver TG content, abnormal liver function indicators (ALT, AST), and abnormal serum TCHO and TG in mice caused by high-sugar and high-fat feeding. Fig.12 .
[0163] In addition, liver delivery of miR-302b inhibited mTORC2 signaling, reduced the abundance of pAKT and pGSK3β, reduced the expression of its downstream transcription factor SREBP1c, and also inhibited the expression of pACLY, ACC, FASN, and SCD, the rate-limiting enzymes in fatty acid de novo synthesis ( Fig.13 ).
[0164] In conclusion, miR-302b can inhibit the de novo synthesis of fatty acids regulated by mTORC2 activity.
[0165] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0166] The above-mentioned embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the attached claims, and the description and drawings may be used to interpret the contents of the claims.
Claims
1. Use of an active ingredient in the preparation of a product for treating non-alcoholic steatohepatitis or non-alcoholic fatty liver disease, wherein the active ingredient comprises at least one of the following (1) to (5): (1) miR-302b, modified miR-302b derivatives or miR-302b mimics; (2) a precursor miRNA, which can be processed into the miRNA described in (1) in the host; (3) a polynucleotide, which can be transcribed by a host to form the precursor miRNA described in (2), and processed to form the miRNA described in (1); (4) an expression vector comprising the miRNA described in (1), the precursor miRNA described in (2), or the polynucleotide described in (3); (5) An agonist of the miRNA described in (1).
2. The use according to claim 1, characterized in that: The non-alcoholic steatohepatitis or the non-alcoholic fatty liver disease has one or more of the following characteristics: (1) Fatty degeneration and fat accumulation; (2) lobular inflammation, ballooning, and fibrosis; and (3) Increased liver index, increased liver TG content, abnormal liver function indicators ALT and AST, and abnormal serum TCHO and TG.
3. The use according to claim 1 or 2, characterized in that: The treatment includes inhibiting excessive fatty acid synthesis under high-sugar and high-fat stress; Optionally, the inhibition is inhibition of de novo fatty acid synthesis in stem cells by inhibiting the mTOCR2 signaling pathway.
4. The use according to claim 1 or 2, characterized in that: The treatment includes inhibition of steatosis and fat accumulation, as well as lobular inflammation, ballooning, and fibrosis.
5. The use according to claim 1 or 2, characterized in that: The treatment includes inhibiting the increase of liver index, alleviating liver function indicators ALT and AST, and reducing TCHO and TG.
6. The use according to claim 1 or 2, characterized in that: The miR-302b includes miR-302b-3p and / or miR-302b-5p; Optionally, the nucleotide sequence of miR-302b includes at least one nucleotide sequence shown in SEQ ID No: 1-2.
7. The use according to claim 1 or 2, characterized in that: The precursor miRNA described in (2) or the polynucleotide described in (3) or the expression vector described in (4) comprises a nucleotide sequence as shown in at least one of SEQ ID Nos: 1 to 2.
8. The use according to claim 1 or 2, characterized in that: The expression vector described in (4) is a viral vector or a non-viral vector.
9. The use according to claim 8, characterized in that: The viral vector comprises one or more of a retroviral vector, a lentivirus, an adenoviral vector, an adeno-associated viral vector, a herpes virus vector, an alphavirus vector, a baculovirus and a vaccinia virus; and / or, The non-viral vector comprises one or more of a plasmid, a bacteriophage, a lipid nanoparticle, a transfection reagent, and an exosome; Optionally, the adeno-associated viral vector includes AAV virus, and the plasmid includes Minicircle.
10. The use according to claim 1 or 2, characterized in that: The product comprises the active ingredient and excipients.
11. The use according to claim 10, characterized in that: The excipients include one or more of solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesive agents, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids and release retardants.
12. The use according to claim 10, characterized in that: The dosage form of the product includes one or more of injection, oral liquid, suspension, emulsion, extract, powder, granule, suppository, aerosol, transfection agent, tablet and capsule.
